MW Lilly says Mounjaro and Zepbound contributed to big revenue boost

By Steve Gelsi

Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a big revenue increase

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

The drugmaker's stock $(LLY)$ rose 1.7% in premarket trading after it said it expects to generate an adjusted 2025 profit of $22.50 a share to $24 a share in 2025. That compares to the FactSet consensus estimate of $22.76 a share for 2025.

Lilly's 2025 revenue target of $58 billion to $61 billion aligns with the FactSet analyst estimate of $58.77 billion. The company reported total 2024 revenue of $45.04 billion.

In the fourth quarter, Lilly's revenue of $13.53 billion matched the analyst estimates.

Adjusted fourth-quarter profit of $5.32 a share topped the analyst estimate of $5.01 per share.

During the quarter, Lilly said it won approval in the U.S. for the use of Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. It also won approval of Omvoh in the U.S. for Crohn's disease.

Lilly said it is still planning to close its acquisition of Scorpion Therapeutics Inc.'s mutant-selective PI3K inhibitor program.

"We enter 2025 with tremendous momentum and look forward to strong financial performance and several important Phase 3 readouts which, if positive, will further accelerate our long-term growth," Lilly Chief Executive David A. Ricks said.

Ahead of Thursday's moves, Lilly's stock was up 9.1% in 2025, while the S&P 500 SPX is up by 3.1%.

-Steve Gelsi

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

February 06, 2025 07:50 ET (12:50 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.